

**Complete listing of all claims, with markings and status identifiers**

(Currently amended claims showing deletions by ~~strike through~~ or [[double brackets]] and additions by underlining)

This listing of claims will replace all prior versions and listings of the claims in the application.

1-11 (Canceled)

12. (Currently amended)      The A chimeric analog of ~~claim 1~~, wherein said chimeric analog is~~[[:]]~~  
Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH<sub>2</sub>~~[[;]]~~,  
or a pharmaceutically acceptable salt thereof.

13-19 (cancelled)

20. (Previously presented)      A method of eliciting a dopamine receptor agonist effect in a subject in need thereof, wherein said method comprises administering to said subject an effective amount of a chimeric analogue of the invention, wherein said chimeric analogue comprises a compound according to claim 12; or a pharmaceutically acceptable salt thereof; and wherein said effective amount is the amount effective to elicit a dopamine receptor agonist effect in said subject.

21-102 (Canceled)